Document is current
Any future updates will be listed below
-
Authors
de Jong, G.
Bartels, L.
Kedde, M.
Verdegaal, E. M. E.
Gillissen, M. A.
Levie, S. E.
Cercel, M. G.
van Hal-van Veen, S. E.
Fatmawati, C.
van de Berg, D.
Yasuda, E.
Claassen, Y. B.
Bakker, A. Q.
van der Burg, S. H.
Schotte, R.
Villaudy, J.
Spits, H.
Hazenberg, M. D.
van Helden, P. M. https://orcid.org/0000-0002-5226-9533
Wagner, K.
-
Funding
Funding for this research was provided by:
KWF Kankerbestrijding (KWF 2014-6557, UVA 2010-4822)
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NWO ICI00004, ZonMW 91715362)
Landsteiner Foundation for Blood Transfusion Research (LSBR 1438F)
- License Information
-
More Information
Article History
Received: 8 May 2020
Accepted: 22 October 2020
First Online: 23 November 2020
Compliance with ethical standards
:
: MK, SEL, MGC, SEHV, CF, DB, EY, YBC, AQB, RS, JV, HS and PMH, have ownership interests in AIMM Therapeutics. MK, MAG, PMH, MDH and HS are inventors on patent WO2016209079A1.
: All animal procedures were carried out in accordance with Dutch and European laws and the institutional guidelines of the Amsterdam UMC. Experiments were approved by the animal experimental committee Amsterdam (DEC) and the central committee for animal experiments (CCD) under license AVD118002016795.
: Patient-derived melanoma samples were isolated with approval of the Medical Ethical Committee of the Leiden University Medical Center after obtaining informed consent, under LUMC study number P04.085.
